“…[59,60] Moreover, several azole-containing agents that are exemplified by linezolid and tedizolid have already been used in clinics for the treatment of infections caused by drug-resistant pathogens including MRSA. [61,62] were active against MRSA, and among them, five hybrids, 28a,b (MIC: 1.0 µg/ml), 29a,b (MIC: 1.0 µg/ml), and 30a (MIC: 0.5 µg/ml), were 8-to 32-fold more potent than clinafloxacin (MIC: 16 µg/ml) and norfloxacin (MIC: 8.0 µg/ml). [63] In particular, hybrid 29a could effectively prevent the development of bacterial resistance, and the mechanistic study indicated that this hybrid could not only intercalate into MRSA DNA, but it could also permeate the MRSA membrane and bind with penicillin-binding protein 2a (PBP2a), and then decrease the expression of three relevant genes in MRSA.…”